Leukemia Articles | Page 3

Nilotinib Approved in Europe for Subset of Pediatric CML
The European Commission has approved nilotinib (Tasigna) for the treatment of pediatric patients with Ph+ chronic myeloid leukemia in the chronic phase.
CAR T-Cell Therapy Approval Starts New Path in Childhood Leukemia
Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.
Umbralisib, Ublituximab, Ibrutinib Triplet Reaches 100% Response in CLL
Loretta J. Nastoupil, MD, discusses the study of the triplet of ublituximab, umbralisib (TGR-1202) and ibrutinib in CLL. 
Acalabrutinib Among Exciting Options Emerging in CLL
Jacqueline Claudia Barrientos, MD, discusses emerging treatment options in CLL.
FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML
The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Profiling CLL Patients Likely to Progress on Available Agents
The next frontier in advancing the field of chronic lymphocytic leukemia (CLL) is identifying patients who will not experience long-term progression-free survival on novel agents.
Guadecitabine Highly Active in AML
More than half of elderly, treatment-naïve patients with AML assigned to treatment with guadecitabine had a composite complete response irrespective of dosage or schedule.
Recognizing Secondary Malignancies in CLL
Alessandra Ferrajoli, MD, discusses the risks of developing secondary malignancies in patients with chronic lymphocytic leukemia.
Triplet Regimen Active Against Relapsed/Refractory Pediatric AML
The combination of clofarabine, cyclophosphamide, and etoposide reached an overall response rate of 41% in a small study of children and adolescents with relapsed/refractory acute myeloid leukemia.
Expert Discusses Ongoing Advances in CLL
Farrukh Awan, MD, discusses novel agents and combinations in CLL, as well as the critical importance of FISH and IGHV testing for patient selection in this population.
Publication Bottom Border
Border Publication